Binding Site

Binding Site, Part of Thermo Fisher Scientific, is committed to improving patient lives worldwide through education, collaboration and innovation.

[Binding Site @TheBindingSite]

From all of us at The Binding Site, we wish you a happy, healthy, and joyful holiday season!

[Binding Site @TheBindingSite]

We are thrilled to announce that Binding Site, a part of Thermo Fisher Scientific, will be featured in seven abstracts at ADLM 2025 in Chicago. Join us to explore groundbreaking research and innovative advancements in protein testing and analysis. https://t.co/zDCbvktW0c

[Binding Site @TheBindingSite]

We are at EHA2025, come visit our booth to take the scientific discussions even further. Come talk to us and let's transform Multiple Myeloma assessment.

#EHA2025

[Binding Site @TheBindingSite]

The EXENT® System, Mass Spectrometry solution for M-protein measurement.

Learn more about use of the EXENT® System in the evaluation of maintenance treatment in Multiple Myeloma patients.
#EHA2025

[Binding Site @TheBindingSite]

EXENT® System, mass spectrometry solution for M-protein measurement.

Learn more about the clinical value of EXENT® System in Multiple Myeloma disease monitoring in patients treated with bispecific antibodies.

[Binding Site @TheBindingSite]

Join us at the European Hematology Association Congress in Milan, Italy, June 12-15. Visit us at booth A.05 and speak to our team.

#EHA2025

[Binding Site @TheBindingSite]

Patient pathways can be very complex the right diagnostic tools are needed from early diagnosis to monitoring. Optilite® Analyser is designed to meet the growing need for specialized protein testing providing accurate results throughout the patient journey https://t.co/f2FfUvDPj3

[Binding Site @TheBindingSite]

We're here at EuroMedLab 2025! Excited to kick off the event and explore the latest advancements in protein testing and analysis. Visit our booth to learn more about our innovative solutions and connect with leading experts in the field.

#EuroMedLab2025 #ProteinTesting

[Binding Site @TheBindingSite]

Join us at EuroMedLab 2025 for an exclusive demo of LabLink xL™! See how this dedicated peer-to-peer QC solution for Binding Site controls on the Optilite® Analyser, provides real-time review, precision, and accurate monitoring. Register👉 https://t.co/6asvtDVZY5
#EuroMedLab2025

[Binding Site @TheBindingSite]

Introducing Binding Site’s solution for special protein testing. Protein testing benefits from dedicated systems for precise and accurate results.

Watch our video to discover how our innovative technologies are transforming the field of protein analysis. https://t.co/1MLP0w82JZ

[Binding Site @TheBindingSite]

Trusted in monoclonal gammopathy diagnostics: Over 1,000 labs worldwide, including leading Myeloma centers trust Freelite assays for their free light chain testing.

https://t.co/otWIJpEz34

[Binding Site @TheBindingSite]

In case you missed it! Dr Katie Horton, Medical Science Liaison for EXENT, introduces the first instalment of our case study series.

We demonstrate how the EXENT® System, can transform the diagnosis of patients with low-level M-protein https://t.co/yeRvgZ2uYx

[Binding Site @TheBindingSite]

While MGUS itself might not always cause symptoms, it's important to monitor patients for any changes in health. Regular follow-ups can significantly improve patient outcomes by allowing for the early detection of progression to Myeloma and the development of comorbidities.

[Binding Site @TheBindingSite]

We are excited to announce our EXENT® System Clinical Case Study Series. These case studies showcase the use of mass spectrometry in real-world patients.

Join us next week for our first case study.

#MassSpectrometry #MultipleMyeloma

[Binding Site @TheBindingSite]

Monoclonal gammopathy of undetermined significance (MGUS) is characterised by the presence of abnormal monoclonal protein in the blood. Understanding the clinical implications of MGUS can help in the early identification of potential complications. 👇

[Binding Site @TheBindingSite]

Monoclonal gammopathy of undetermined significance (MGUS) can lead to complications such as bone fractures or kidney problems. Awareness of the clinical significance of MGUS and regular monitoring of patients is essential for effective patient management: https://t.co/Qjo4X5w1ak

[Binding Site @TheBindingSite]

In a Swedish multicentric study by Veskovski et al. (2024), experts in haematology highlight the critical impact of serum free light chain analysis methods on myeloma diagnosis.

Learn how Freelite ® assays can improve patient outcomes here: https://t.co/zgbYACd9UO

[Binding Site @TheBindingSite]

Monoclonal gammopathy of undetermined significance (MGUS) may not require treatment. However, it is important to be aware of its potential to progress to malignancies such as Multiple Myeloma or to develop comorbidities like renal insufficiency. https://t.co/NT6NSZIlnx

[Binding Site @TheBindingSite]

The annual @ASH_hematology conference is the largest hematology conference in the world, with the 66th ASH conference being the biggest one to date. We are committed to advancing diagnostic technologies to support this vital work.

Learn more: https://t.co/B2gGDXmYcw

[Binding Site @TheBindingSite]

Freelite® assays play a pivotal role in accurate diagnosis, treatment monitoring, and disease management to provide a better patient outcome.

Read these patient cases which reinforce why Freelite assays have been trusted by the medical community worldwide for over 20 years.